AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Candel Therapeutics shares surge 12.33% after-hours after announcing virtual R&D event on December 5, 2025.
ByAinvest
Wednesday, Dec 3, 2025 5:27 pm ET1min read
Candel Therapeutics (CADL) surged 12.33% in after-hours trading following multiple positive developments. The stock’s rally aligns with recent announcements, including the company’s third-quarter 2025 financial results, a virtual R&D event scheduled for December 5, 2025, and interim data from its phase 1b CAN-3110 trial showing promise in recurrent glioblastoma. Additional catalysts included a $130 million term loan facility with Trinity Capital and appointments of leading immunology experts to its advisory board. These updates, coupled with presentations at major conferences like SITC 2025 and ASTRO 2025, reinforced investor confidence in Candel’s pipeline of viral immunotherapies and clinical advancements. The after-hours jump reflects optimism over its strategic partnerships, capital raising, and progress in next-generation cancer treatments.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet